193 related articles for article (PubMed ID: 24122399)
1. Propensity score matched lesion-based comparison of long-term clinical and angiographic outcomes after placement of sirolimus (Cypher Bx Velocity) and paclitaxel (TAXUS Express)-eluting stents for de novo native coronary stenosis.
Nakano Y; Ishikawa T; Hino S; Mutoh M
Cardiovasc Interv Ther; 2014 Apr; 29(2):93-101. PubMed ID: 24122399
[TBL] [Abstract][Full Text] [Related]
2. Propensity score-matched lesion-based comparison of mid-term angiographic outcomes of TAXUS Liberté with Cypher Bx Velocity stents for de novo native coronary stenosis and in patients with diabetes.
Suzuki T; Ishikawa T; Nakano Y; Hino S; Mutoh M
Intern Med; 2014; 53(12):1265-73. PubMed ID: 24930644
[TBL] [Abstract][Full Text] [Related]
3. Retrospective comparison of midterm clinical and angiographic outcomes after the implantation of paclitaxel- and sirolimus-eluting stents for de novo coronary complex lesions in nonrandomized Japanese patients.
Ishikawa T; Nakano Y; Mutoh M
Intern Med; 2012; 51(19):2695-701. PubMed ID: 23037458
[TBL] [Abstract][Full Text] [Related]
4. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
[TBL] [Abstract][Full Text] [Related]
5. Long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement following rotablation for severely calcified lesions: a retrospective nonrandomized study.
Tsutsumi J; Ishikawa T; Nakano Y; Yoshimura M; Mutoh M
Cardiovasc Interv Ther; 2015 Jan; 30(1):29-37. PubMed ID: 25069959
[TBL] [Abstract][Full Text] [Related]
6. Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison.
Miyamoto T; Ishikawa T; Nakano Y; Mutoh M
Cardiovasc Interv Ther; 2017 Jan; 32(1):24-35. PubMed ID: 26979599
[TBL] [Abstract][Full Text] [Related]
7. One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents.
Chevalier B; Moulichon R; Teiger E; Brunel P; Metzger JP; Pansieri M; Carrie D; Stoll HP; Wittebols K; Spaulding C; Fajadet J;
J Interv Cardiol; 2012 Dec; 25(6):586-95. PubMed ID: 22994863
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus- and paclitaxel-eluting stents in comparison with balloon angioplasty for treatment of in-stent restenosis.
Iofina E; Haager PK; Radke PW; Langenberg R; Blindt R; Ortlepp J; Kühl H; Hanrath P; Hoffmann R
Catheter Cardiovasc Interv; 2005 Jan; 64(1):28-34. PubMed ID: 15619307
[TBL] [Abstract][Full Text] [Related]
9. Drug-eluting stents for the treatment of ostial coronary lesions: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.
Chen J; Li JJ; Chen JL; Qiao SB; Xu B; Yang YJ; Gao RL; Qin XW; Yuan JQ; Yao M; Wu YJ; Liu HB; Dai J; You SJ
Coron Artery Dis; 2008 Nov; 19(7):507-11. PubMed ID: 18923247
[TBL] [Abstract][Full Text] [Related]
10. Long-term angiographic outcomes of sirolimus- and paclitaxel-eluting stent placement in diabetes, long lesions, and small vessels.
Nakano Y; Ishikawa T; Mutoh M
Cardiovasc Interv Ther; 2015 Oct; 30(4):327-37. PubMed ID: 25673511
[TBL] [Abstract][Full Text] [Related]
11. Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) study.
Mehilli J; Byrne RA; Tiroch K; Pinieck S; Schulz S; Kufner S; Massberg S; Laugwitz KL; Schömig A; Kastrati A;
J Am Coll Cardiol; 2010 Jun; 55(24):2710-6. PubMed ID: 20226618
[TBL] [Abstract][Full Text] [Related]
12. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of the clinical and angiographic outcomes of the sirolimus-eluting stent and the bare-metal stent in 2031 nonrandomized consecutive de novo native coronary lesions.
Kubota T; Ishikawa T; Mutoh M
Intern Med; 2011; 50(21):2463-70. PubMed ID: 22041343
[TBL] [Abstract][Full Text] [Related]
14. Midterm outcomes of bare-metal stenting after primary stenting for ST-segment elevated myocardial infarctions in the drug-eluting stent era: a propensity score-matched comparison with sirolimus-eluting stent.
Nakata K; Ishikawa T; Nakano Y; Yoshimura M; Mutoh M
Cardiovasc Interv Ther; 2015 Jul; 30(3):234-43. PubMed ID: 25420640
[TBL] [Abstract][Full Text] [Related]
15. Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.
Di Lorenzo E; Sauro R; Varricchio A; Carbone G; Cortese G; Capasso M; Lanzillo T; Manganelli F; Mariello C; Siano F; Pagliuca MR; Stanco G; Rosato G; De Luca G
Circulation; 2009 Sep; 120(11):964-72. PubMed ID: 19720939
[TBL] [Abstract][Full Text] [Related]
16. Post-discharge clinical and angiographic outcomes of patients presenting within 48h of STEMI treated with paclitaxel- or sirolimus-eluting stents.
Ishikawa T; Mutoh M; Nakano Y; Suzuki T; Nakata K; Murakami A; Miyamoto T; Yoshimura M
J Cardiol; 2012 Sep; 60(3):174-9. PubMed ID: 22727627
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness of sirolimus- and paclitaxel-eluting stents for small coronary artery lesions.
Park KH; Park SW; Hong MK; Kim YH; Lee BK; Park DW; Choi BR; Kim MJ; Park KM; Lee CW; Cheong SS; Kim JJ; Park SJ
Catheter Cardiovasc Interv; 2006 Apr; 67(4):589-94. PubMed ID: 16547937
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial.
Kufner S; Byrne RA; de Waha A; Schulz S; Joner M; Laugwitz KL; Kastrati A;
Cardiovasc Revasc Med; 2014 Mar; 15(2):69-75. PubMed ID: 24684757
[TBL] [Abstract][Full Text] [Related]
19. Longer-term outcomes of paclitaxel stent implantation as an initial treatment strategy for sirolimus-eluting stent restenosis.
Levisay JP; Price MJ; Shaba W; Lee SS; Stinis CP; Miller L; Teirstein PS
J Invasive Cardiol; 2010 May; 22(5):216-9. PubMed ID: 20440037
[TBL] [Abstract][Full Text] [Related]
20. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
